Drug discovery programs routinely perform pharmacokinetic (PK) studies in mouse to prioritize lead compounds based on anticipated exposure-efficacy and exposure-toxicity relationships. Due to logistical and/or technical issues, the strain of mouse in early discovery PK studies may not always match the strain in toxicity or efficacy studies. This elicits the question: do appreciable strain-dependent differences in PK parameters exist to an extent that would warrant conducting PK studies in a strain that matches efficacy and toxicity models? To understand the impact that strain may have on PK parameters, we selected 8 marketed drugs with well characterized absorption, distribution, metabolism, and excretion properties and diverse structures to perform PK studies in three common mouse strains (BALB/c, C57BL/6, and CD-1). Some statistical strain-dependent differences were observed, however, we found good general agreeance of PK between strains: 88%, 100%, 75%, and 88% of compounds were within two-fold across strains for Cl, Vss, t1/2, and F, respectively. Overall, we recommend that an approach using a single strain of mouse is appropriate for discovery screening PK studies, provided that proper caution is exercised. SIGNIFICANCE STATEMENT Pharmaceutical research programs routinely execute mouse PK studies to characterize PK properties of compounds as a filtering criterion to advance candidates through the pipeline as well as to support efficacy and toxicology studies. The mouse strain in discovery PK studies may not match the strain in efficacy and tox studies. Currently, there is gap in the literature addressing if differences in PK parameters across mouse strains exist such that multiple PK studies are warranted. The results from this study indicated that the PK properties of clinically used drugs between mouse strains are within an acceptable range such that single strain PK is appropriate.
11 February 2025 in Journal of Medicinal Chemistry
Covalent inhibition of the KRASG12C oncoprotein has emerged as a promising therapeutic approach for the treatment of nonsmall cell lung cancer (NSCLC). The identification of KRASG12C inhibitors has typically relied on the high-throughput screening (HTS) of libraries of cysteine-reactive small molecules or on the attachment of cysteine-reactive warheads to noncovalent binders of KRAS. Such screening approaches have historically been limited in the size and diversity of molecules that could be effectively screened. DNA-encoded library (DEL) screening has emerged as a promising approach to accelerate the preparation and screening of incredibly large and diverse chemical libraries. Here, we describe the design and synthesis of a covalent DEL to screen ∼16 million compounds against KRASG12C. We additionally describe the hit identification, validation, and structure-based optimization that culminated in the identification of a series of structurally novel, potent, and selective covalent inhibitors of KRASG12C with good pharmacokinetic profiles and promising in vivo pharmacodynamic effects.
It is well-recognized that nonspecific binding of a drug within an in vitro assay (fu) can have a large impact on in vitro to in vivo correlations of intrinsic clearance. Typically, this value is determined experimentally across multiple species in the drug discovery stage. Herein we examine the feasibility of using a single species (rat) as a surrogate for other species using a panel of small molecules representing highly diverse structures and physiochemical classes. The study demonstrated that 86% and 92% of the tested compounds measured in mouse, dog, monkey, and human were within two-fold of rat values for fu in microsomes and hepatocytes, respectively. One compound, amiodarone, exhibited unique species-dependent binding where the fu was approximately 10-fold higher in human microsomes and 20-fold higher in human hepatocytes compared to the average of the other species tested. Overall, these data indicate that using a single species (rat) fu as a surrogate for other major species, including human, is a means to increase the throughput of measuring non-specific binding in vitro.
12 October 2015 in Rapid Communications in Mass Spectrometry
Free (unbound) drug concentration at the site of action is the key determinant of biological activity since only unbound drugs can exert pharmacological and toxicological effects. Unbound drug concentration in tumors for solid cancers is needed to understand/explain/predict pharmacokinetics (PK), pharmacodynamics (PD), and efficacy relations. Fraction unbound (fu) in tumors is usually determined across several xenografted tumors derived from various cell lines in the drug discovery stage, which is time-consuming and a resource burden. In this study, we determined the fu values for a set of diverse compounds (comprising acid, base, neutral, zwitterion, and covalent drugs) across five different xenografted tumors and five commercially available mouse tissues to explore the correlation of fu between tumors and the possibility of surrogate tissue(s) for tumor fu (fu,tumor) determination. The cross-tumor comparison showed fu,tumor values across tumors are largely comparable, and systematic tissue vs. tumor comparison demonstrated only lung tissue had comparable fu to all five tumors (fu values within 2-fold change for >80% compounds in both comparisons). These results indicated mouse lung tissue can be used as a surrogate matrix for fu,tumor assay. This study will increase efficiency in fu,tumor assessment and reduce animal use (adapting the 3Rs principle: replace, reduce, and refine) in drug discovery. Significance Statement The free drug concept is a well-accepted principle in drug discovery research. Currently, fu,tumor is determined in several tumors derived from different cell lines to estimate free drug concentrations of a compound. The results from this study indicated fu,tumor across xenografted tumors are comparable and fu,tumor can be estimated using a surrogate tissue, mouse lung. The results will increase efficiency in fu,tumor assessment and reduce animal use in drug discovery.